Neuraxis

Neuraxis Intangibles/Assets

The Intangible Assets to Total Assets Ratio of Neuraxis (NRXS) as of Nov 22, 2026 is 2.03 %. In the previous year, Intangible Assets to Total Assets Ratio was 21.22 % — a change of -90.43% (lower).

Intangibles/Assets

2.03 %

YoY

-90.43%

Last updated:

Intangible Assets to Total Assets Ratio of Neuraxis is 2024 2.03 % . Intangible Assets to Total Assets Ratio of Neuraxis was 2023 21.22 % . It decreases by -90.43% lower compared to the previous year.

The Neuraxis Intangibles/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangibles/Assets
Date
Intangibles/Assets
Jan 1, 2020
1.08 USD
Jan 1, 2021
2.63 USD
Jan 1, 2022
5.40 USD
Jan 1, 2023
21.22 USD
Jan 1, 2024
2.03 USD
The Neuraxis Intangibles/Assets history
YEARIntangibles/AssetsYoY
2.03 %-90.43%
21.22 %+292.68%
5.40 %+105.45%
2.63 %+144.54%
1.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Intangible Assets to Total Assets Ratio of Neuraxis is 2.03 % in 2024.

Intangible Assets to Total Assets Ratio of Neuraxis changed from 21.22 % to 2.03 %, representing a -90.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets to Total Assets Ratio Neuraxis since 2006 – with annual values, charts, and detailed analysis.

The Intangibles/Assets ratio shows the proportion of total assets that are intangible. High ratios are common in technology and pharmaceutical companies.

Intangible Assets to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets to Total Assets Ratio's Neuraxis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neuraxis

All Key Metrics — Neuraxis